Literature DB >> 15804051

14-3-3 protein in CSF: an early predictor of SIV CNS disease.

Kristi L Helke1, Suzanne E Queen, Patrick M Tarwater, Jadwiga Turchan-Cholewo, Avindra Nath, M Christine Zink, David N Irani, Joseph L Mankowski.   

Abstract

In neurons, 14-3-3 proteins regulate diverse processes, including signal transduction, neurotransmitter production, and apoptosis by binding to target proteins, but the role 14-3-3 proteins play in the pathogenesis of central nervous system (CNS) disease remains unclear. To examine the relationship between presence of 14-3-3 protein in cerebrospinal fluid (CSF) and encephalitis in the SIV/macaque model of HIV CNS disease, CSF levels of 14-3-3 protein were measured by quantitative immunoblotting throughout infection in 6 SIV-infected pigtailed macaques. Beginning during asymptomatic infection and continuing until death, CSF levels of 14-3-3 were elevated in 4 of 6 SIV-infected animals. Animals with 14-3-3 protein in CSF had the highest viral loads in the CSF after acute infection and the highest levels of both viral RNA and protein in brain (p < 0.001). In contrast, the presence of 14-3-3 protein in CSF was not associated with CNS microglial/macrophage activation measured by quantitative immunohistochemical staining for CD68 (p = 0.13). CSF levels of 14-3-3 protein may be a valuable marker of early neuronal damage, CNS viral replication, and CNS disease progression in HIV-infected individuals.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15804051     DOI: 10.1093/jnen/64.3.202

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  8 in total

Review 1.  14-3-3s are potential biomarkers for HIV-related neurodegeneration.

Authors:  Diana Morales; Efthimios C M Skoulakis; Summer F Acevedo
Journal:  J Neurovirol       Date:  2012-07-19       Impact factor: 2.643

2.  Cerebrospinal Fluid Biomarkers of Simian Immunodeficiency Virus Encephalitis : CSF Biomarkers of SIV Encephalitis.

Authors:  Stephanie J Bissel; Julia Kofler; Julia Nyaundi; Michael Murphey-Corb; Stephen R Wisniewski; Clayton A Wiley
Journal:  J Neuroimmune Pharmacol       Date:  2016-04-08       Impact factor: 4.147

3.  Human immunodeficiency virus type 1 gp120-mediated disruption of tight junction proteins by induction of proteasome-mediated degradation of zonula occludens-1 and -2 in human brain microvascular endothelial cells.

Authors:  Shinichi Nakamuta; Hiroshi Endo; Youichiro Higashi; Aoi Kousaka; Hiroshi Yamada; Mihiro Yano; Hiroshi Kido
Journal:  J Neurovirol       Date:  2008-05       Impact factor: 2.643

4.  Proteomic and metabolomic strategies to investigate HIV-associated neurocognitive disorders.

Authors:  Gurudutt Pendyala; Howard S Fox
Journal:  Genome Med       Date:  2010-03-30       Impact factor: 11.117

5.  Enteric ganglionitis in rhesus macaques infected with simian immunodeficiency virus.

Authors:  Marlene S Orandle; Ronald S Veazey; Andrew A Lackner
Journal:  J Virol       Date:  2007-03-28       Impact factor: 5.103

6.  YKL-40, a marker of simian immunodeficiency virus encephalitis, modulates the biological activity of basic fibroblast growth factor.

Authors:  Dafna Bonneh-Barkay; Stephanie J Bissel; Gouji Wang; Kenneth N Fish; Georgina C B Nicholl; Samuel W Darko; Rafael Medina-Flores; Michael Murphey-Corb; Premeela A Rajakumar; Julia Nyaundi; John W Mellors; Robert Bowser; Clayton A Wiley
Journal:  Am J Pathol       Date:  2008-06-13       Impact factor: 4.307

7.  Synaptic proteins linked to HIV-1 infection and immunoproteasome induction: proteomic analysis of human synaptosomes.

Authors:  Benjamin B Gelman; Trung P Nguyen
Journal:  J Neuroimmune Pharmacol       Date:  2009-08-20       Impact factor: 4.147

Review 8.  The accelerated simian immunodeficiency virus macaque model of human immunodeficiency virus-associated neurological disease: from mechanism to treatment.

Authors:  Janice E Clements; Joseph L Mankowski; Lucio Gama; M Christine Zink
Journal:  J Neurovirol       Date:  2008-08       Impact factor: 2.643

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.